Matrix metalloproteinase (MMP) inhibitors and methods of use thereof

A method of treating a disease mediated by macrophage elastase (MMP-12) in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises at least one pharmaceutically acceptable carrier and a compound of formula (I):

• or a tautomer, stereoisomer, pharmaceutically acceptable salt, or hydrate thereof,
• wherein:
• ring A is an optionally substituted heteroaryl;
• Q is CR2 or N;
• R1 is hydrogen or alkyl;
• each R2 is independently hydrogen, alkyl, halo, hydroxyl, haloalkyl, alkoxy, alkylthio, amino, amido, alkylamino, aminoalkyl, cyano, hydroxyalkyl, —(CH2)pC(O)OR6, or (CH2)pOC(O)R6;
• R3 is hydrogen, halo, or alkyl;
• each R4 and R5 is independently hydrogen or alkyl;
• each R6 is independently hydrogen or alkyl, wherein the alkyl is unsubstituted or substituted with one or more groups independently selected from amino, hydroxyl, halo, and alkoxy;
• X is S or O;
• Y is:
• n is 1, 2, 3 or 4;
• and
• p is 0, 1, 2, 3, 4, or 5;
• wherein the disease is selected from the group consisting of sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.